Imaging and technologies for prostate cancer. Where are we now—where do we go?
While some approaches have matured, others are still in their infancy. We have learned that Active Surveillance is safe in... Read More
While some approaches have matured, others are still in their infancy. We have learned that Active Surveillance is safe in... Read More
Since sipuleucel-T approval in 2010, the treatment landscape for metastatic castration-resistant prostate cancer (mCRPC) now includes the androgen-receptor signaling pathway... Read More